« Back
Home /
(R)-Pirtobrutinib

(R)-Pirtobrutinib

Item no.	HY-131328A-25mg
Manufacturer	MedChem Express
CASRN	2101700-14-3
Amount	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	99.78
Formula	C22H21F4N5O3
Citations	[1]Gomez E B , et al. Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations[J]. Blood, 2019, 134(Supplement_1):4644-4644.
Smiles	O=C(C1=C(N)N([C@H](C)C(F)(F)F)N=C1C2=CC=C(CNC(C3=CC(F)=CC=C3OC)=O)C=C2)N
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	(R)-LOXO-305
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Targets	Btk
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	479.43
Product Description	(R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib. Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations[1].
Manufacturer - Research Area	Others
Solubility	DMSO : 200 mg/mL (ultrasonic)
Manufacturer - Pathway	Protein Tyrosine Kinase/RTK
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-131328A-25mg-safety-datasheet.pdf